Scandinavian ChemoTech receives a patent in Japan for its unique tumor-specific and dynamic cancer treatment
ChemoTech has been notified that the company's previously approved patent application regarding the unique functions that today relate to the TSE technology has now also been approved in Japan.The patent refers to D-EECT, which was the development name for the technological platform that is the basis for ChemoTech's tumor-specific electroporation technology (TSE), which has been shown in clinical publications to have both efficacy and safety as well as potential in the treatment of various forms of cancer. The technology has been documented to be able to create an effective treatment,